Why Morphic Holding Stock Is Skyrocketing Today

Why Morphic Holding Stock Is Skyrocketing Today

More important than its financial results, the biopharmaceutical company announced results from a clinical trial and other developments regarding collaboration agreements with big-name drugmakers. Morphic Holding reported interim data from a phase 1 clinical trial for MORF-057, a potential medicine for inflammatory bowel disease (IBD).